AbbVie Inc. (ABBV)
AbbVie: A Strong Investment Opportunity In Neurological And Oncology Breakthroughs
AbbVie presents a strong long-term investment opportunity, driven by its strategic focus on neuroscience and IBD treatments, despite challenges from Humira's decline. Tavapadon and other neuroscience drugs offer substantial growth potential, addressing unmet medical needs in Parkinson's and other neurological conditions. Skyrizi and Rinvoq are rapidly growing, offsetting Humira's revenue decline, and positioning AbbVie to capture significant market share in the expanding IBD market.
Dividend Stocks With Strong Q4 Seasonality
Entering October is the strongest period of the year for three-month returns, and shorter-term returns are also some of the best. Here we take a look at 30 dividend stocks in the S&P 500 that have been the best Q4 performers over the last ten years. 2024 has been a strong year already for high-yielding stocks, and now they have Q4 seasonality as another tailwind.
AbbVie: $200 Peak (Rating Downgrade)
AbbVie has transitioned beyond Humira's exclusivity loss, with strong growth from Skyrizi and Rinvoq, targeting $27 billion in sales by 2027. The stock has surged to $200, now trading at 16x 2025 EPS targets, making it less of a bargain. AbbVie's dividend yield is 3.1%, with a potential hike to 3.3% in October, but debt remains high at over $60 billion.
AbbVie's Skyrizi And Rinvoq Deserve The Premium Growth Valuation
AbbVie's high-growth investment thesis is undeniable indeed, despite Humira's painful patent expiry and the erosion observed in its sales thus far. Our optimism arises from Skyrizi's/Rinvoq's promising double-digit growth, excellent ex-Humira portfolio sales growth, and the management's raised FY2024/FY2027 guidance. ABBV's balance sheet health remains reasonable as well, attributed to the projected expansion in its Free Cash Flow generation over the next few years.
5 Best Dividend Growth Stocks to Buy in October
These five stocks are known for their generous dividend programs and robust business models.
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
EU withdraws marketing authorisation for Abbvie's hepatitis C drug
The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's hepatitis C drug Exviera at the request of the company.
AbbVie stock analysis: Rinvoq and Skyrizi are big catalysts
AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V
ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
15 Best Dividend Stocks for Lifelong Passive Income
Dividend sustainability trumps high yields when selecting stocks for passive income. The featured companies span diverse sectors including healthcare, consumer goods, retail, finance, and real estate.
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
